ARCHIVES

CMS Issues Coverage Decision For Provenge in Prostate Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

Chart of FY 1991 Budget For NCI By Mechanism

February 2, 1990

FDA Accepts Advisory Committee’s Recommendations On NDA, Labeling

October 26, 1979

Micafungin Bests Fluconazole In Phase III Antifungal Trial

November 29, 2002

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

April 30, 2004

“5 A Day” Review Underway to Check Program’s Health at NCI.

March 31, 2000